$STOK
Stoke Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024092738 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $4.894M $4.831M
YoY Change 47.94% -294.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.69M $13.04M
YoY Change 23.58% 27.44%
% of Gross Profit
Research & Development $22.21M $21.14M
YoY Change 9.54% 2.85%
% of Gross Profit
Depreciation & Amortization $540.0K $548.0K
YoY Change -15.63% -10.31%
% of Gross Profit
Operating Expenses $34.90M $34.17M
YoY Change 14.26% 11.02%
Operating Profit -$30.00M -$29.34M
YoY Change 10.17% -11.79%
Interest Expense $3.545M $3.695M
YoY Change 33.72% 43.94%
% of Operating Profit
Other Income/Expense, Net $3.573M $3.647M
YoY Change 32.73% 39.84%
Pretax Income -$26.43M -$25.70M
YoY Change 7.7% -16.18%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$26.43M -$25.70M
YoY Change 7.69% -16.18%
Net Earnings / Revenue -540.05% -531.88%
Basic Earnings Per Share -$0.47 -$0.46
Diluted Earnings Per Share -$0.47 -$0.46
COMMON SHARES
Basic Shares Outstanding 52.65M 52.12M
Diluted Shares Outstanding 56.34M 55.77M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $239.2M $282.0M
YoY Change 11.4% 21.83%
Cash & Equivalents $150.0M $193.5M
Short-Term Investments $89.18M $88.51M
Other Short-Term Assets $3.809M $4.287M
YoY Change -10.78% 15.9%
Inventory
Prepaid Expenses $9.837M $10.35M
Receivables
Other Receivables
Total Short-Term Assets $253.6M $297.0M
YoY Change 10.26% 20.62%
LONG-TERM ASSETS
Property, Plant & Equipment $4.333M $4.770M
YoY Change -30.3% -26.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $29.95M
YoY Change
Other Assets $494.0K $494.0K
YoY Change -17.67% -13.18%
Total Long-Term Assets $39.71M $10.76M
YoY Change 302.3% 0.71%
TOTAL ASSETS
Total Short-Term Assets $253.6M $297.0M
Total Long-Term Assets $39.71M $10.76M
Total Assets $293.3M $307.8M
YoY Change 22.27% 19.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.485M $3.945M
YoY Change -19.21% 153.53%
Accrued Expenses $15.17M $14.50M
YoY Change 17.6% 25.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $49.87M $44.50M
YoY Change 97.87% 103.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.050M $3.606M
YoY Change 218.04% 121.36%
Total Long-Term Liabilities $11.34M $20.55M
YoY Change -72.8% -54.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.87M $44.50M
Total Long-Term Liabilities $11.34M $20.55M
Total Liabilities $61.21M $65.05M
YoY Change -8.5% -2.51%
SHAREHOLDERS EQUITY
Retained Earnings -$480.3M -$453.9M
YoY Change 28.13% 29.56%
Common Stock $5.000K $5.000K
YoY Change 25.0% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $232.1M $242.7M
YoY Change
Total Liabilities & Shareholders Equity $293.3M $307.8M
YoY Change 22.27% 19.79%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$26.43M -$25.70M
YoY Change 7.69% -16.18%
Depreciation, Depletion And Amortization $540.0K $548.0K
YoY Change -15.63% -10.31%
Cash From Operating Activities -$21.62M -$17.48M
YoY Change 25.23% -19.83%
INVESTING ACTIVITIES
Capital Expenditures $103.0K $46.00K
YoY Change -73.59% -94.52%
Acquisitions
YoY Change
Other Investing Activities -$29.90M -$88.23M
YoY Change -299.34% -462.92%
Cash From Investing Activities -$30.00M -$88.28M
YoY Change -305.23% -476.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.159M 120.7M
YoY Change 1356.96% 251254.17%
NET CHANGE
Cash From Operating Activities -21.62M -17.48M
Cash From Investing Activities -30.00M -88.28M
Cash From Financing Activities 8.159M 120.7M
Net Change In Cash -43.46M 14.90M
YoY Change 1989.42% 765.49%
FREE CASH FLOW
Cash From Operating Activities -$21.62M -$17.48M
Capital Expenditures $103.0K $46.00K
Free Cash Flow -$21.72M -$17.52M
YoY Change 23.05% -22.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1307000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2661000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2564000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6532000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
704000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5828000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5499000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2277000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3551000
CY2024Q2 stok Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted
OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted
5828000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001623526
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#LiabilitiesCurrent
CY2024Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38938
dei Entity Registrant Name
EntityRegistrantName
Stoke Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1144582
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Wiggins Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
430-8200
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
STOK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52647799
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193476000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191442000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88506000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9952000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10345000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11320000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
75000
CY2024Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
305000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
64000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4287000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2561000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
296994000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
215339000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
494000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5499000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6611000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4770000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5823000
CY2024Q2 us-gaap Assets
Assets
307757000
CY2023Q4 us-gaap Assets
Assets
228342000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3945000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1695000
CY2024Q2 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
14500000
CY2023Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
13815000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
26051000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
15309000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44496000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30819000
CY2024Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16946000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
33074000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3606000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4884000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
20552000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
37958000
CY2024Q2 us-gaap Liabilities
Liabilities
65048000
CY2023Q4 us-gaap Liabilities
Liabilities
68777000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52305641
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52305641
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45918233
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45918233
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
696637000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
561433000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-24000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453918000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401849000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
242709000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
159565000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
307757000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228342000
CY2024Q2 us-gaap Revenues
Revenues
4831000
CY2023Q2 us-gaap Revenues
Revenues
-2481000
us-gaap Revenues
Revenues
9048000
us-gaap Revenues
Revenues
2671000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21136000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20551000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43504000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40182000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13037000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10230000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23258000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20442000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
34173000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
30781000
us-gaap Operating Expenses
OperatingExpenses
66762000
us-gaap Operating Expenses
OperatingExpenses
60624000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29342000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33262000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57714000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57953000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3695000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2567000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6121000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4670000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-476000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
84000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3647000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2608000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5645000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4754000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25695000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30654000
us-gaap Net Income Loss
NetIncomeLoss
-52069000
us-gaap Net Income Loss
NetIncomeLoss
-53199000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55765948
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55765948
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44188464
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44188464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51288222
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51288222
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43367032
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43367032
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25695000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30654000
us-gaap Net Income Loss
NetIncomeLoss
-52069000
us-gaap Net Income Loss
NetIncomeLoss
-53199000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
219000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
796000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
219000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
796000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25710000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30435000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52060000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52403000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
184849000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22545000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
577000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5887000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
158000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
153000
CY2023Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
44743000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
213822000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30654000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
219000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6760000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
190195000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
159565000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26374000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5410000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
168000
CY2024Q1 stok Shares Sold As Part Of Controlled Equity Offering Sales Agreement Value
SharesSoldAsPartOfControlledEquityOfferingSalesAgreementValue
1299000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
140342000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25695000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7427000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
766000
CY2024Q2 stok Issuance Of Common Stock Upon Follow On Offering Net Of Underwriting Discounts Commissions And Offering Costs
IssuanceOfCommonStockUponFollowOnOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts
119884000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
242709000
us-gaap Profit Loss
ProfitLoss
-52069000
us-gaap Profit Loss
ProfitLoss
-53199000
us-gaap Depreciation
Depreciation
1111000
us-gaap Depreciation
Depreciation
1208000
stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
-313000
stok Amortization And Accretion Of Marketable Securities
AmortizationAndAccretionOfMarketableSecurities
-114000
us-gaap Share Based Compensation
ShareBasedCompensation
12837000
us-gaap Share Based Compensation
ShareBasedCompensation
12647000
stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
1112000
stok Reduction In Carrying Amount Of Operating Lease Right Of Use Assets
ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets
1106000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
993000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
310000
stok Increase Decrease In Accounts Payable Accrued Liabilities And Opertaing Leases
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOpertaingLeases
1658000
stok Increase Decrease In Accounts Payable Accrued Liabilities And Opertaing Leases
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOpertaingLeases
-4076000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5386000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-418000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42043000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43156000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
88232000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
58000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1004000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
77562000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-78290000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76558000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
168000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
206000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1016000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
153000
stok Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement
ProceedsFromIssuanceOfCommonStockInControlledEquityOfferingSalesAgreement
1299000
stok Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement
ProceedsFromIssuanceOfCommonStockInControlledEquityOfferingSalesAgreement
44743000
stok Proceeds From Follow On Offering Net Of Underwriting Discounts Commissions And Offering Costs
ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsCommissionsAndOfferingCosts
119884000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
122367000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45102000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2034000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
78504000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192011000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
114125000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194045000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192629000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span></p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193476000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192060000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
75000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
494000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
569000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
194045000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
192629000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88521000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
15000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88506000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9976000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
24000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
9952000
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3540000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5611000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2149000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
651000
CY2024Q2 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5497000
CY2023Q4 stok Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
4634000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2277000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2062000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1037000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
857000
CY2024Q2 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
14500000
CY2023Q4 stok Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
13815000
CY2018Q3 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
23000
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q3 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
900000
CY2018Q3 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.03
CY2018Q3 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2018-12-10
CY2018Q4 stok Area Of Space Subject To Operating Lease
AreaOfSpaceSubjectToOperatingLease
2485
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q4 stok Number Of Renewal Option To Extend Operating Lease Terms
NumberOfRenewalOptionToExtendOperatingLeaseTerms
1
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2018Q4 stok Operating Lease Cost Per Year
OperatingLeaseCostPerYear
200000
CY2018Q4 stok Annual Base Rent Increase Percentage For Operating Lease
AnnualBaseRentIncreasePercentageForOperatingLease
0.025
CY2018Q4 stok Operating Lease Commencement Date
OperatingLeaseCommencementDate
2019-05-01
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1003
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
897712
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
30900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7427000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6760000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12837000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12647000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-25695000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-30654000
us-gaap Net Income Loss
NetIncomeLoss
-52069000
us-gaap Net Income Loss
NetIncomeLoss
-53199000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55765948
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55765948
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44188464
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44188464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51288222
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51288222
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43367032
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43367032
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10455561
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10225504
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0

Files In Submission

Name View Source Status
0000950170-24-092738-index-headers.html Edgar Link pending
0000950170-24-092738-index.html Edgar Link pending
0000950170-24-092738.txt Edgar Link pending
0000950170-24-092738-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stok-20240630.htm Edgar Link pending
stok-20240630.xsd Edgar Link pending
stok-ex10_1.htm Edgar Link pending
stok-ex10_2.htm Edgar Link pending
stok-ex10_3.htm Edgar Link pending
stok-ex31_1.htm Edgar Link pending
stok-ex31_2.htm Edgar Link pending
stok-ex32_1.htm Edgar Link pending
stok-ex32_2.htm Edgar Link pending
stok-20240630_htm.xml Edgar Link completed